News | December 10, 2009

Partnership To Create Surgical Repair of Mitral Valve Chordae

December 10, 2009 – An exclusive license agreement between On-X Life Technologies and the Cleveland Clinic will create a system of products intended to improve and simplify the replacement of damaged or severed mitral valve chordae. The system is the creation of co-inventors A. Marc Gillinov, M.D., a staff cardiac surgeon at Cleveland Clinic, and Michael K. Banbury, M.D., of Christiana Care’s Center for Heart and Vascular Health, and will be codeveloped with the On-X LTI New Product Development team.

Surgical repair of the mitral valve includes the insertion of a cloth-covered ring around the valve to bring the leaflets into contact with each other (annuloplasty), removal of redundant/loose segments of the leaflets, and resuspension of the leaflets with artificial cords (chordal replacement). Replacement of diseased mitral valve chordae with expanded polytetrafluoroethylene (ePTFE) sutures is an established technique with good long-term results. Various techniques have been described to assist the surgeon to establish the correct replacement chordal length.

“For the past three decades, there has been great focus on the roles of leaflet resection and annuloplasty for mitral valve repair in patients with mitral valve prolapse. More recently, surgeons have recognized the value of using artificial chordae to correct prolapse,” said Dr. Gillinov. “With current techniques, chordal replacement is technically challenging. The hope is to assist cardiac surgeons by providing a simple method for chordal replacement.”

“The surgical approach to mitral valve repair appears to be a method by which a long-term satisfactory outcome can be achieved,” said Dr. Banbury. “It is our expectation that the surgical tools we will develop with On-X LTI will further enable the surgical approach and enhance the consistency of surgical outcomes, providing patients with the best opportunity for a solution to their mitral incompetence.”

Approximately 50,000 mitral valve repair procedures are performed annually in the United States. Mitral valve repair is one of the fastest growing procedures in cardiac surgery due to the excellent long-term outcome. In a minority of cases the mitral valve may not be surgically repaired and must be replaced with a prosthetic valve.

For more information: www.onxlti.com


Related Content

News | Cardiovascular Surgery

April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home April 23, 2024
Home
News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
News | Cardiovascular Surgery

December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...

Home December 20, 2023
Home
News | Cardiovascular Surgery

December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...

Home December 18, 2023
Home
News | Cardiovascular Surgery

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
News | Cardiovascular Surgery

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

Home October 25, 2023
Home
Subscribe Now